# Characterizing the Use of High-Dose Amoxicillin for the Treatment of Bacteremia

**Authors:** Julia Lloyd, Kathleen Lau, Cindy San, Victor Leung, Colin Lee

PMC · DOI: 10.3390/pathogens15010054 · 2026-01-06

## TL;DR

High-dose oral amoxicillin was found to be safe and effective for treating uncomplicated bacteremia, with most patients recovering fully.

## Contribution

This study provides empirical evidence on the safety and efficacy of high-dose oral amoxicillin for treating bacteremia.

## Key findings

- 92% of patients were cured with high-dose oral amoxicillin.
- No adverse events, relapses, or deaths were observed.
- 28% of patients were readmitted, but mostly unrelated to the original infection.

## Abstract

Treatment of bacteremia has traditionally consisted of a 7–14-day course of intravenous (IV) antibiotics. Transitioning from IV to oral (PO) antibiotics in uncomplicated cases of Gram-negative and Gram-positive bacteremia is non-inferior to a complete course of IV antibiotics. High-dose oral amoxicillin has been used in practice for treating bacteremia but has limited safety and efficacy data. We conducted a retrospective chart review between June 2022 and June 2024 to characterize the use of high-dose amoxicillin and evaluate its efficacy and safety. A convenient sample size of 100 patients was used. Patients admitted to hospital who received at least one dose of high-dose amoxicillin (1 g PO TID) for the treatment of bacteremia were included. Patients undergoing hemodialysis and patients receiving amoxicillin for other infections were excluded. The average patient was a 60-year-old male (66% male) with a Gram-positive respiratory or skin source bacteremia. The median time to transition to oral amoxicillin was 5 days. The median duration of total treatment was 14 days. Respiratory sources were treated for a shorter duration, whereas skin sources were treated for longer. Readmission to hospital occurred in 28% of cases. The majority of readmissions were unrelated to the original infection, and 92% of patients were cured. There were no observed adverse events, bacteremia relapses, or deaths. In this observational study, transitioning to high-dose oral amoxicillin was primarily used for treatment of uncomplicated respiratory and skin infections with secondary bacteremia. A high rate of clinical success was observed with high-dose PO amoxicillin, with no adverse events reported.

## Linked entities

- **Chemicals:** amoxicillin (PubChem CID 33613)
- **Diseases:** bacteremia (MONDO:0005229)

## Full-text entities

- **Diseases:** infection (MESH:D007239), respiratory and skin infections (MESH:D012141), Bacteremia (MESH:D016470)
- **Chemicals:** Amoxicillin (MESH:D000658)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12845038/full.md

---
Source: https://tomesphere.com/paper/PMC12845038